Over a 30-40 year time period dozens of studies involving dietary fish oil supplements and even prescription products such as OMACOR-Lovaza (Relient, GSK), EPANOVA (AstraZeneca) have not been able to demonstrate a clinical CVD benefit. Only one OMEGA-3 prescription product has proven this clinical benefit. VASCEPA, Amarin Corp.). In fact, professional medical organizations like the American Heart Association, European Medicines Agency, Canadian Thrombosis Society, and American Diabetes Association have issued guidelines or scientific statements that dietary supplements are not approved by the FDA or other governing agencies, nor are they to be substituted for approved products such as VASCEPA.
The American Heart Association issued a Scientific Advisory in August of 2019 recognizing that elevated triglycerides may be a causal factor for CVD; that dietary supplements are not recommended, nor FDA approved, to treat medical conditions; and that positive outcomes results were demonstrated in REDUCE-IT using VASCEPA®.
Finally, the respected Mayo Clinic has said that “fish oil supplements seems to have no benefits to heart health.
News 
Market Data 
Discover 
AI
